Drugs / Pacmilimab
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03013491 | Jan 2017 → Oct 2020 | cancer, lymphoma | CytomX Therapeutics | Terminated | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT04596150 | Dec 2020 → Jun 2023 | hormone receptor-positive breast cancer, triple-negative breast carcinoma | CytomX Therapeutics | Completed | No outcome recorded |
| Phase 2 | NCT03993379 | Nov 2019 → May 2020 | melanoma | CytomX Therapeutics | Terminated | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pacmilimab | “A Phase 2, Open-Label Study to Evaluate the Safety and Antitumor Activity of Praluzatamab Ravtansine (CX-2009) in Advanced HR-Positive/HER2-Negative Breast Cancer and of...” NCT04596150 ↗1“CX-072 (pacmilimab), a Probody (®) PD-L1 inhibitor, in advanced or recurrent solid tumors” PMID 34301809 ↗ Jul 2021 |
| Known as | CX-072 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04596150 ↗ |
| Known as | CX-072 PROBODY | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297563 ↗ |
| Action | Inhibit | “CX-072 (pacmilimab), a Probody (®) PD-L1 inhibitor” PMID 34301809 ↗ Jul 2021 |
| Modality | Monoclonal antibody | — CHEMBL4297563 ↗ |
| Route | Intravenous | “Intravenous administration of the CX-072 of 1200 mg administered every 3 weeks (Q3W)” NCT04596150 ↗ |
| Target | CD274 | “Programmed cell death 1 ligand 1 binding agent” CHEMBL4297563 ↗ |